In vitro drug testing using patient-derived ovarian cancer organoids.

ABSTRACT:

Background

Ovarian cancer is the most lethal gynecological cancer. As the primary treatment, chemotherapy has a response rate of only 60-70% in advanced stages, and even lower as a second-line treatment. Despite guideline recommendations, which drugs will be most effective remains unclear. Thus, a strategy to prioritize chemotherapy options is urgently needed. Cancer organoids have recently emerged as a method for in vitro drug testing. However, limited clinical correlations have been assessed with test results from cancer organoids, particularly in gynecological cancers. We therefore aimed to generate patient-derived organoids (PDOs) of ovarian cancer, to assess their drug sensitivities and correlations with patient clinical outcomes.

Methods

PDOs were generated from fresh

SUBMITTER: Chen LY 

PROVIDER: S-EPMC11445862 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature